AXSM - Axsome Therapeutics, Inc. News

HC Wainwright & Co. Reiterates Buy on Axsome Therapeutics, Maintains $290 Price Target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Axsome Therapeutics (NASDAQ:AXSM) w

Axsome Therapeutics Dosed First Patient in SUMMIT Phase 3 Trial of AXS-05 For Smoking Cessation

Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company leading a new era in the treatm

globenewswire.com

Axsome Therapeutics Initiates SUMMIT Phase 3 Trial of AXS-05 in Smoking Cessation

NEW YORK, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceu

fool.com

Amgen vs. Axsome Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?

Amgen is a diversified pharmaceutical giant with high net margins. It reported nearly $8.1 billion i

fool.com

Axsome Therapeutics Stock Is Up 16% Year to Date. Why Wall Street Thinks It Has Even More Room to Ru

Axsome Therapeutics is performing well as it continues to expand its approved portfolio. The company

BlackRock Inc. Invests $759.70 Million in Axsome Therapeutics, Inc. $AXSM

BlackRock Inc. bought a new position in Axsome Therapeutics, Inc. (NASDAQ: AXSM) during the second q

Here’s How Much You Would Have Made Owning Axsome Therapeutics Stock In The Last 5 Years

Axsome Therapeutics (NASDAQ:AXSM) has outperformed the market over the past 5 years by 46.84% on an

If You Invested $100 In Axsome Therapeutics Stock 10 Years Ago, You Would Have This Much Today

Axsome Therapeutics (NASDAQ:AXSM) has outperformed the market over the past 10 years by 26.64% on an

Mizuho Maintains Outperform on Axsome Therapeutics, Raises Price Target to $316

Mizuho analyst Graig Suvannavejh maintains Axsome Therapeutics (NASDAQ:AXSM) with a Outperform an

Axsome's Q2 Earnings Meet Estimates, Auvelity Drives Y/Y Revenues

AXSM's Q2 earnings meet estimates, but revenues miss forecasts. Auvelity and other product sales dri

seekingalpha.com

Axsome Therapeutics Q2 Earnings Review: I Just Can't See The Value Proposition

Axsome Therapeutics, Inc. reported Q2 2026 net product revenue growth of 46% year-on-year, but risin

Morgan Stanley Maintains Equal-Weight on Axsome Therapeutics, Raises Price Target to $251

Morgan Stanley analyst Sean Laaman maintains Axsome Therapeutics (NASDAQ:AXSM) with a Equal-Weigh

RBC Capital Maintains Outperform on Axsome Therapeutics, Lowers Price Target to $297

RBC Capital analyst Leonid Timashev maintains Axsome Therapeutics (NASDAQ:AXSM) with a Outperform

Axsome Therapeutics Analysts Increase Their Forecasts Following Q2 Results

Axsome Therapeutics (NASDAQ:AXSM) reported Q2 losses of 99 cents per share and sales of $218.4 milli

Guggenheim Maintains Buy on Axsome Therapeutics, Raises Price Target to $275

Guggenheim analyst Yatin Suneja maintains Axsome Therapeutics (NASDAQ:AXSM) with a Buy and raises

Wells Fargo Maintains Overweight on Axsome Therapeutics, Raises Price Target to $256

Wells Fargo analyst Benjamin Burnett maintains Axsome Therapeutics (NASDAQ:AXSM) with a Overweigh

Target To Rally Around 12%? Here Are 10 Top Analyst Forecasts For Tuesday

Wall Street analysts changed outlook on top names. See complete view of all changes, upgrades, downg

Needham Maintains Buy on Axsome Therapeutics, Raises Price Target to $268

Needham analyst Ami Fadia maintains Axsome Therapeutics (NASDAQ:AXSM) with a Buy and raises the p

seekingalpha.com

Axsome Therapeutics, Inc. (AXSM) Q2 2026 Earnings Call Transcript

Axsome (AXSM) Reports Q2 Earnings: What Key Metrics Have to Say

While the top- and bottom-line numbers for Axsome (AXSM) give a sense of how the business performed

Axsome Therapeutics (AXSM) Reports Q2 Loss, Misses Revenue Estimates

Axsome Therapeutics (AXSM) came out with a quarterly loss of $0.99 per share in line with the Zacks

marketbeat.com

Axsome Therapeutics Q2 Earnings Call Highlights

Axsome Therapeutics NASDAQ: AXSM reported second-quarter 2026 net product revenue of $218 million, u

Axsome Therapeutics Q2 EPS $(0.99) Misses $(0.83) Estimate, Sales $218.400M Miss $221.230M Estimate

Axsome Therapeutics (NASDAQ:AXSM) reported quarterly losses of $(0.99) per share which missed the an

globenewswire.com

Axsome Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

Total 2Q 2026 net product revenue of $218.4 million, representing 46% year-over-year growth AUVELITY

Axsome Therapeutics (NASDAQ:AXSM) CEO Sells $997,007.00 in Stock

Axsome Therapeutics, Inc. (NASDAQ: AXSM - Get Free Report) CEO Herriot Tabuteau sold 4,660 shares of

Assenagon Asset Management S.A. Cuts Stock Holdings in Axsome Therapeutics, Inc. $AXSM

Assenagon Asset Management S.A. lowered its holdings in Axsome Therapeutics, Inc. (NASDAQ: AXSM) by

Countdown to Axsome (AXSM) Q2 Earnings: Wall Street Forecasts for Key Metrics

Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Axsome (AXSM), delve into so

Analysts Estimate Axsome Therapeutics (AXSM) to Report a Decline in Earnings: What to Look Out for

Axsome (AXSM) doesn't possess the right combination of the two key ingredients for a likely earnings

Mizuho Maintains Outperform on Axsome Therapeutics, Lowers Price Target to $306

Mizuho analyst Graig Suvannavejh maintains Axsome Therapeutics (NASDAQ:AXSM) with a Outperform an

New Strong Sell Stocks for July 31st

BLND, AXSM and BCML have been added to the Zacks Rank #5 (Strong Sell) List on July 31, 2026.

New Strong Sell Stocks for July 29th

ARDX, BDORY and AXSM have been added to the Zacks Rank #5 (Strong Sell) List on July 29, 2026.

New Strong Sell Stocks for July 27th

LEN, AXSM and SAM have been added to the Zacks Rank #5 (Strong Sell) List on July 27, 2026.

Caxton Associates LLP Makes New Investment in Axsome Therapeutics, Inc. $AXSM

Caxton Associates LLP bought a new stake in Axsome Therapeutics, Inc. (NASDAQ: AXSM) during the unde

finbold.com

These major drug stocks rally after Trump's zero tariff announcement

President Donald Trump has announced that all generic drugs imported into the United States would co

This Fortinet Analyst Is No Longer Bearish; Here Are Top 4 Upgrades For Tuesday

Wall Street analysts upgraded Fortinet, Goldman Sachs, Adaptive Biotechnologies, and Five Below, wit

This Insmed Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

Top Wall Street analysts change outlook on top stocks. For analyst rating changes, see https://www.b

BMO Capital Initiates Coverage On Axsome Therapeutics with Outperform Rating, Announces Price Target

BMO Capital analyst Malcolm Hoffman initiates coverage on Axsome Therapeutics (NASDAQ:AXSM) with

HC Wainwright & Co. Reiterates Buy on Axsome Therapeutics, Maintains $290 Price Target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Axsome Therapeutics (NASDAQ:AXSM) w

Axsome Therapeutics Says FDA Accepts NDA For AXS-12 For Treatment Of Cataplexy In Narcolepsy; PDUFA

Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company leading a new era in the treatm

9 Health Care Stocks Whale Activity In Today’s Session

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

HC Wainwright & Co. Reiterates Buy on Axsome Therapeutics, Maintains $290 Price Target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Axsome Therapeutics (NASDAQ:AXSM) w

RBC Capital Maintains Outperform on Axsome Therapeutics, Raises Price Target to $304

RBC Capital analyst Leonid Timashev maintains Axsome Therapeutics (NASDAQ:AXSM) with a Outperform

Axsome Therapeutics Doses First Patient In FOCUS-2 Phase 3 Trial Of Solriamfetol For Children With A

FOCUS-2 (Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol) is a Phase 3,

Axsome Therapeutics Announces First Patient Dosed In FOCUS-3 Phase 3 Trial Evaluating Solriamfetol A

Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company leading a new era in the treatm

TD Cowen Maintains Buy on Axsome Therapeutics, Raises Price Target to $300

TD Cowen analyst Joseph Thome maintains Axsome Therapeutics (NASDAQ:AXSM) with a Buy and raises t

10 Health Care Stocks Whale Activity In Today's Session

'Health Officials Close To U.S. Secretary Kennedy Explored Ban Of Some Widely Used Antidepressants'

Health officials explored restricting specific antidepressants among SSRI drugs-sources

Global Business Travel Group Posts Upbeat Q1 Results, Joins Cabaletta Bio, Aura Biosciences And Othe

Global Business Travel Group Inc (GBTG), a NYSE-listed company, saw its stock rise 57% on Monday af

Earnings Scheduled For May 4, 2026